Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists

Abstract

We previously reported the design and synthesis of a small-molecule drug conjugate (SMDC) platform that demonstrated several advantages over antibody–drug conjugates (ADCs) in terms of in vivo pharmacokinetics, solid tumor penetration, definitive chemical structure, and adaptability for modular synthesis. Constructed on a tri-modal SMDC platform derived from 1,3,5-triazine (TZ) that consists of a targeting moiety (Lys-Urea-Glu) for prostate-specific membrane antigen (PSMA), here we report a novel class of chemically identical theranostic small-molecule prodrug conjugates (T-SMPDCs), [18/19F]F-TZ(PSMA)-LEGU-TLR7, for PSMA-targeted delivery and controlled release of toll-like receptor 7 (TLR7) agonists to elicit de novo immune response for cancer immunotherapy. In vitro competitive binding assay of [19F]F-TZ(PSMA)-LEGU-TLR7 showed that the chemical modification of Lys-Urea-Glu did not compromise its binding affinity to PSMA. Receptor-mediated cell internalization upon the PSMA binding of [18F]F-TZ(PSMA)-LEGU-TLR7 showed a time-dependent increase, indicative of targeted intracellular delivery of the theranostic prodrug conjugate. The designed controlled release of gardiquimod, a TLR7 agonist, was realized by a legumain cleavable linker. We further performed an in vivo PET/CT imaging study that showed significantly higher uptake of [18F]F-TZ(PSMA)-LEGU-TLR7 in PSMA+ PC3-PIP tumors (1.9 ± 0.4% ID/g) than in PSMA− PC3-Flu tumors (0.8 ± 0.3% ID/g) at 1 h post-injection. In addition, the conjugate showed a one-compartment kinetic profile and in vivo stability. Taken together, our proof-of-concept biological evaluation demonstrated the potential of our T-SMPDCs for cancer immunomodulatory therapies.

Selenium-Based Drug Development for Antioxidant and Anticancer Activity

“…There is a limit to current treatments' efficacy for the prevention and treatment of cancer [45,46]. The creation of novel pharmaceuticals [47,48], radiopharmaceuticals [49][50][51], therapeutic targets, and modified molecules with improved drug transport and efficacy have received attention in recent years [52,53]. − from PMNs [39].…”

Advances in the Chemistry of 2,4,6‐Tri(thiophen‐2‐yl)‐1,3,5‐triazine

“… [18] Triazine based systems have also been of immense biological significance. [ 19 , 20 ] The symmetric triazine isomer, that is, 1,3,5‐triazine also referred as s ‐triazine ( 1.3 ) is the most interesting and important isomer that has been used in variety of applications. The importance of s ‐triazine in material chemistry can be attributed mainly to its high electron affinity, symmetry and different type of supramolecular interactions that it gives rise to.…”

In Silico Approach in the Evaluation of Pro-Inflammatory Potential of Polycyclic Aromatic Hydrocarbons and Volatile Organic Compounds through Binding Affinity to the Human Toll-Like Receptor 4

“…Both identify main bacterial components, namely lipoproteins in TLR2 and lipopolysaccharides (LPS) in TLR4. TLR2, TLR4, and TLR7 are the best characterized pattern recognition receptors (PRRs), which identify invading pathogens outside the cell as well as intracellular pathogens captured in endosomes [ 1 , 2 , 3 ]. TLR4 activation occurs through dimerization of the receptor where it forms a homodimer.…”